ID   MEF2A_RAT               Reviewed;         495 AA.
AC   Q2MJT0; Q66HD7;
DT   24-MAR-2009, integrated into UniProtKB/Swiss-Prot.
DT   07-FEB-2006, sequence version 1.
DT   24-JUL-2024, entry version 115.
DE   RecName: Full=Myocyte-specific enhancer factor 2A;
GN   Name=Mef2a;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, AND FUNCTION.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=17367767; DOI=10.1016/j.cardiores.2007.02.007;
RA   Wang Y.-X., Qian L.-X., Liu D., Yao L.-L., Jiang Q., Yu Z., Gui Y.-H.,
RA   Zhong T.-P., Song H.-Y.;
RT   "Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancer
RT   factor 2a to control embryonic cardiac contractility.";
RL   Cardiovasc. Res. 74:290-303(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, PHOSPHORYLATION AT SER-400, SUMOYLATION AT LYS-395, ACETYLATION
RP   AT LYS-395, AND MUTAGENESIS OF LYS-395 AND SER-400.
RX   PubMed=16484498; DOI=10.1126/science.1122513;
RA   Shalizi A., Gaudilliere B., Yuan Z., Stegmueller J., Shirogane T., Ge Q.,
RA   Tan Y., Schulman B., Harper J.W., Bonni A.;
RT   "A calcium-regulated MEF2 sumoylation switch controls postsynaptic
RT   differentiation.";
RL   Science 311:1012-1017(2006).
RN   [4]
RP   SUMOYLATION, AND FUNCTION.
RX   PubMed=17855618; DOI=10.1523/jneurosci.0361-07.2007;
RA   Shalizi A., Bilimoria P.M., Stegmueller J., Gaudilliere B., Yang Y.,
RA   Shuai K., Bonni A.;
RT   "PIASx is a MEF2 SUMO E3 ligase that promotes postsynaptic dendritic
RT   morphogenesis.";
RL   J. Neurosci. 27:10037-10046(2007).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-235 AND SER-255, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Transcriptional activator which binds specifically to the
CC       MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific
CC       genes. Also involved in the activation of numerous growth factor- and
CC       stress-induced genes. Mediates cellular functions not only in skeletal
CC       and cardiac muscle development, but also in neuronal differentiation
CC       and survival. Plays diverse roles in the control of cell growth,
CC       survival and apoptosis via p38 MAPK signaling in muscle-specific and/or
CC       growth factor-related transcription. In cerebellar granule neurons,
CC       phosphorylated and sumoylated MEF2A represses transcription of NUR77
CC       promoting synaptic differentiation. Associates with chromatin to the
CC       ZNF16 promoter (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16484498, ECO:0000269|PubMed:17367767,
CC       ECO:0000269|PubMed:17855618}.
CC   -!- SUBUNIT: Binds DNA as a homo- or heterodimer (By similarity). Dimerizes
CC       with MEF2D. Interacts with HDAC7. Interacts with PIAS1; the interaction
CC       enhances sumoylation. Interacts with HDAC4, HDAC9 and SLC2A4RG.
CC       Interacts (via the N-terminal) with MAPK7; the interaction results in
CC       the phosphorylation and transcriptional activity of MEF2A (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00251,
CC       ECO:0000269|PubMed:17367767}.
CC   -!- PTM: Constitutive phosphorylation on Ser-400 promotes Lys-395
CC       sumoylation thus preventing acetylation at this site. Dephosphorylation
CC       on Ser-400 by PPP3CA upon neuron depolarization promotes a switch from
CC       sumoylation to acetylation on residue Lys-395 leading to inhibition of
CC       dendrite claw differentiation. Phosphorylation on Thr-304 and Thr-311
CC       are the main sites involved in p38 MAPK signaling and activate
CC       transcription. Phosphorylated on these sites by MAPK14/p38alpha and
CC       MAPK11/p38beta, but not by MAPK13/p38delta nor by MAPK12/p38gamma.
CC       Phosphorylation on Ser-400 by CDK5 induced by neurotoxicity inhibits
CC       MEF2A transcriptional activation leading to apoptosis of cortical
CC       neurons. Phosphorylation on Thr-304, Thr-311 and Ser-347 can be induced
CC       by EGF (By similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylation on Lys-395 is enhanced by PIAS1 and represses
CC       transcriptional activity. Phosphorylation on Ser-400 is required for
CC       sumoylation. Has no effect on nuclear location nor on DNA binding.
CC       Sumoylated with SUMO1 and, to a lesser extent with SUMO2 and SUMO3.
CC       PIASx facilitates sumoylation in postsynaptic dendrites in the
CC       cerebellar cortex and promotes their morphogenesis (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Acetylation on Lys-395 activates transcriptional activity.
CC       Acetylated by p300 on several sites in diffentiating myocytes.
CC       Acetylation on Lys-4 increases DNA binding and transactivation (By
CC       similarity). Hyperacetylation by p300 leads to enhanced cardiac myocyte
CC       growth and heart failure. {ECO:0000250, ECO:0000269|PubMed:16484498}.
CC   -!- PTM: Proteolytically cleaved in cerebellar granule neurons on several
CC       sites by caspase 3 and caspase 7 following neurotoxicity.
CC       Preferentially cleaves the CDK5-mediated hyperphosphorylated form which
CC       leads to neuron apoptosis and transcriptional inactivation (By
CC       similarity). {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ323505; ABC55063.1; -; mRNA.
DR   EMBL; BC081907; AAH81907.1; -; mRNA.
DR   RefSeq; NP_001014057.1; NM_001014035.1.
DR   RefSeq; XP_017444797.1; XM_017589308.1.
DR   AlphaFoldDB; Q2MJT0; -.
DR   SMR; Q2MJT0; -.
DR   MINT; Q2MJT0; -.
DR   STRING; 10116.ENSRNOP00000068554; -.
DR   iPTMnet; Q2MJT0; -.
DR   PhosphoSitePlus; Q2MJT0; -.
DR   PaxDb; 10116-ENSRNOP00000065122; -.
DR   GeneID; 309957; -.
DR   KEGG; rno:309957; -.
DR   AGR; RGD:1359360; -.
DR   CTD; 4205; -.
DR   RGD; 1359360; Mef2a.
DR   eggNOG; KOG0014; Eukaryota.
DR   InParanoid; Q2MJT0; -.
DR   OrthoDB; 448298at2759; -.
DR   PhylomeDB; Q2MJT0; -.
DR   Reactome; R-RNO-525793; Myogenesis.
DR   PRO; PR:Q2MJT0; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0000785; C:chromatin; ISO:RGD.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISS:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; ISS:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0046332; F:SMAD binding; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0061337; P:cardiac conduction; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR   GO; GO:0048813; P:dendrite morphogenesis; IMP:UniProtKB.
DR   GO; GO:0006351; P:DNA-templated transcription; ISO:RGD.
DR   GO; GO:0070375; P:ERK5 cascade; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; ISO:RGD.
DR   GO; GO:0000165; P:MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0000002; P:mitochondrial genome maintenance; ISO:RGD.
DR   GO; GO:0048311; P:mitochondrion distribution; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0055005; P:ventricular cardiac myofibril assembly; ISO:RGD.
DR   CDD; cd00265; MADS_MEF2_like; 1.
DR   Gene3D; 3.40.1810.10; Transcription factor, MADS-box; 1.
DR   InterPro; IPR022102; HJURP_C.
DR   InterPro; IPR050142; MADS-box/MEF2_TF.
DR   InterPro; IPR033896; MADS_MEF2-like.
DR   InterPro; IPR002100; TF_MADSbox.
DR   InterPro; IPR036879; TF_MADSbox_sf.
DR   PANTHER; PTHR48019:SF109; MYOCYTE-SPECIFIC ENHANCER FACTOR 2A; 1.
DR   PANTHER; PTHR48019; SERUM RESPONSE FACTOR HOMOLOG; 1.
DR   Pfam; PF12347; HJURP_C; 1.
DR   Pfam; PF00319; SRF-TF; 1.
DR   PRINTS; PR00404; MADSDOMAIN.
DR   SMART; SM00432; MADS; 1.
DR   SUPFAM; SSF55455; SRF-like; 1.
DR   PROSITE; PS00350; MADS_BOX_1; 1.
DR   PROSITE; PS50066; MADS_BOX_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Apoptosis; Developmental protein; Differentiation;
KW   DNA-binding; Isopeptide bond; Neurogenesis; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..495
FT                   /note="Myocyte-specific enhancer factor 2A"
FT                   /id="PRO_0000366970"
FT   DOMAIN          3..57
FT                   /note="MADS-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00251"
FT   DNA_BIND        58..86
FT                   /note="Mef2-type"
FT                   /evidence="ECO:0000255"
FT   REGION          175..225
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          242..271
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          266..283
FT                   /note="Required for interaction with MAPKs"
FT                   /evidence="ECO:0000250"
FT   REGION          382..495
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        195..218
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        382..397
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        420..435
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        436..454
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            213..214
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000305"
FT   SITE            454..455
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         59
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         98
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         235
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         249
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q02078"
FT   MOD_RES         255
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         304
FT                   /note="Phosphothreonine; by MAPK7 and MAPK14"
FT                   /evidence="ECO:0000250|UniProtKB:Q02078"
FT   MOD_RES         311
FT                   /note="Phosphothreonine; by MAPK7 and MAPK14"
FT                   /evidence="ECO:0000250|UniProtKB:Q02078"
FT   MOD_RES         347
FT                   /note="Phosphoserine; by MAPK7"
FT                   /evidence="ECO:0000250|UniProtKB:Q02078"
FT   MOD_RES         395
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16484498"
FT   MOD_RES         400
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000269|PubMed:16484498"
FT   MOD_RES         407
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60929"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q02078"
FT   CROSSLNK        395
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   MUTAGEN         395
FT                   /note="K->R: Abolishes sumoylation."
FT                   /evidence="ECO:0000269|PubMed:16484498"
FT   MUTAGEN         400
FT                   /note="S->A: Abolishes K-395 sumoylation. Enhances K-395
FT                   acetylation. Enhances transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:16484498"
FT   CONFLICT        223
FT                   /note="G -> S (in Ref. 2; AAH81907)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        231
FT                   /note="D -> N (in Ref. 2; AAH81907)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        396
FT                   /note="T -> S (in Ref. 2; AAH81907)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   495 AA;  53254 MW;  8ED69528402E613E CRC64;
     MGRKKIQITR IMDERNRQVT FTKRKFGLMK KAYELSVLCD CEIALIIFNS SNKLFQYAST
     DMDKVLLKYT EYNEPHESRT NSDIVEALNK KEHRGCDSPD PDTSYVLTPH TEEKYKKINE
     EFDNMMRNHK IAPGLPPQNF SMSVTVPVTS PNALSYTNPG SSLVSPSLAA SSTLAESSML
     SPPPATLHRN VSPGAPQRPP STGSAGGMLS TTDLTVPNGA GNGPVGNGFV DSRASPNLIG
     NTGANSVGKV MPTKSPPPPG GGSVGMNSRK PDLRVVIPPS SKGMMPPLNA QRISSSQATQ
     PLATPVVSVT TPSLPPQGLV YSAMPTAYNT DYSLTSADLS ALQGFTSPGM LSLGQASAWQ
     QHHLGQAALS SLVAGGQLSQ GSNLSINTNQ NINIKTEPIS PPRDRMTPSG FQQQQQQQPQ
     QQPPPQPPQP QPQPRQEMGR SPVDSLSSSS SSYDGSDRED PRGDFHSPIV LGRPPNAEDR
     ESPSVKRMRM DTWVT
//
